CA3166944A1 - Treatment of upper facial lines - Google Patents
Treatment of upper facial lines Download PDFInfo
- Publication number
- CA3166944A1 CA3166944A1 CA3166944A CA3166944A CA3166944A1 CA 3166944 A1 CA3166944 A1 CA 3166944A1 CA 3166944 A CA3166944 A CA 3166944A CA 3166944 A CA3166944 A CA 3166944A CA 3166944 A1 CA3166944 A1 CA 3166944A1
- Authority
- CA
- Canada
- Prior art keywords
- asn
- modified bont
- bont
- amino acid
- units
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Massaging Devices (AREA)
- Percussion Or Vibration Massage (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2003813.9 | 2020-03-16 | ||
| GBGB2003813.9A GB202003813D0 (en) | 2020-03-16 | 2020-03-16 | Treatment of upper facial lines |
| PCT/GB2021/050659 WO2021186167A1 (en) | 2020-03-16 | 2021-03-16 | Treatment of upper facial lines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3166944A1 true CA3166944A1 (en) | 2021-09-23 |
Family
ID=70453766
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3166944A Pending CA3166944A1 (en) | 2020-03-16 | 2021-03-16 | Treatment of upper facial lines |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230346674A1 (enExample) |
| EP (1) | EP4120997A1 (enExample) |
| JP (2) | JP2023517727A (enExample) |
| KR (1) | KR20220154739A (enExample) |
| CN (1) | CN115279337A (enExample) |
| AU (1) | AU2021238928A1 (enExample) |
| BR (1) | BR112022018457A2 (enExample) |
| CA (1) | CA3166944A1 (enExample) |
| GB (1) | GB202003813D0 (enExample) |
| TW (1) | TW202140522A (enExample) |
| WO (1) | WO2021186167A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11707510B2 (en) * | 2018-02-16 | 2023-07-25 | Preclinics Discovery Gmbh | Nucleic acid-based botulinum neurotoxin for therapeutic use |
| US12011284B2 (en) * | 2020-05-19 | 2024-06-18 | Peachy Corp. | Systems and methods for preventing and treating wrinkles |
| GB202206362D0 (en) * | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
| GB202206361D0 (en) * | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of a facial dystonia |
| GB202206348D0 (en) * | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of limb spasticity |
| GB202214232D0 (en) | 2022-09-28 | 2022-11-09 | Ispen Biopharm Ltd | Clostridial neurotoxins comprising an activating exogenous protease cleavage site |
| GB202214229D0 (en) | 2022-09-28 | 2022-11-09 | Ipsen Biopharm Ltd | Clostridial neurotoxins comprising an activating endosomal protease cleavage site |
| WO2025093845A1 (en) * | 2023-11-01 | 2025-05-08 | Ipsen Biopharm Limited | Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines |
| AU2023471835A1 (en) * | 2023-11-01 | 2026-04-30 | Ipsen Biopharm Limited | Use of chimeric botulinum toxin a for treating blepharospasm and hemifacial spasm |
| GB202318884D0 (en) | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| US7220422B2 (en) * | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
| DK2154151T3 (da) | 2005-09-19 | 2011-09-05 | Allergan Inc | Clostridiumtoksinaktiverbare clostridiumtoksiner |
| EP2524963B1 (en) | 2011-05-19 | 2018-10-31 | Ipsen Bioinnovation Limited | Methods for the manufacture of proteolytically processed polypeptides |
| MX359480B (es) | 2012-05-30 | 2018-09-28 | President And Fellows Of Harvard College Star | Neurotoxina botulínica diseñada. |
| JP6156954B2 (ja) | 2012-11-21 | 2017-07-05 | イプセン バイオイノベーション リミテッド | タンパク分解性にプロセシングされたポリペプチドの製造方法 |
| GB201312317D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Cationic neurotoxins |
| GB201407525D0 (en) | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| RU2746736C2 (ru) | 2015-03-26 | 2021-04-20 | Президент Энд Феллоуз Оф Гарвард Колледж | Сконструированный ботулинический нейротоксин |
| GB201517450D0 (en) | 2015-10-02 | 2015-11-18 | Ipsen Biopharm Ltd | Method |
| GB201607901D0 (en) * | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
-
2020
- 2020-03-16 GB GBGB2003813.9A patent/GB202003813D0/en not_active Ceased
-
2021
- 2021-03-16 WO PCT/GB2021/050659 patent/WO2021186167A1/en not_active Ceased
- 2021-03-16 EP EP21714255.3A patent/EP4120997A1/en active Pending
- 2021-03-16 AU AU2021238928A patent/AU2021238928A1/en active Pending
- 2021-03-16 CA CA3166944A patent/CA3166944A1/en active Pending
- 2021-03-16 JP JP2022555816A patent/JP2023517727A/ja active Pending
- 2021-03-16 CN CN202180021505.4A patent/CN115279337A/zh active Pending
- 2021-03-16 KR KR1020227035398A patent/KR20220154739A/ko active Pending
- 2021-03-16 US US17/911,503 patent/US20230346674A1/en not_active Abandoned
- 2021-03-16 BR BR112022018457A patent/BR112022018457A2/pt unknown
- 2021-03-16 TW TW110109317A patent/TW202140522A/zh unknown
-
2026
- 2026-03-09 JP JP2026036776A patent/JP2026097980A/ja active Pending
- 2026-04-03 US US19/638,809 patent/US20260207462A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4120997A1 (en) | 2023-01-25 |
| GB202003813D0 (en) | 2020-04-29 |
| KR20220154739A (ko) | 2022-11-22 |
| TW202140522A (zh) | 2021-11-01 |
| WO2021186167A1 (en) | 2021-09-23 |
| US20230346674A1 (en) | 2023-11-02 |
| US20260207462A1 (en) | 2026-07-23 |
| JP2026097980A (ja) | 2026-06-16 |
| CN115279337A (zh) | 2022-11-01 |
| AU2021238928A1 (en) | 2022-09-01 |
| JP2023517727A (ja) | 2023-04-26 |
| BR112022018457A2 (pt) | 2022-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230346674A1 (en) | Treatment of Upper Facial Lines | |
| US20250179461A1 (en) | Modified Bont/A for Use in the Treatment of a Disorder Affecting an Eyelid Muscle of a Subject | |
| EP4401759B1 (en) | Modified bont/a for use in the treatment of cervical dystonia | |
| US20230248811A1 (en) | Treatment of Limb Spasticity | |
| US20250177278A1 (en) | Treatment of upper facial lines | |
| US20250213662A1 (en) | Bont/a for use in treating a facial dystonia | |
| US20250302928A1 (en) | Treatment of cervical dystonia | |
| RU2846028C1 (ru) | Лечение морщин верхней части лица | |
| RU2841585C1 (ru) | Модифицированный ботулинический нейротоксин для лечения спастичности конечностей | |
| HK40078498A (en) | Treatment of upper facial lines | |
| WO2025093845A1 (en) | Use of high dose chimeric botulinum toxin a for the treatment of upper facial lines | |
| HK40110371A (en) | Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject | |
| HK40078497A (en) | Modified botulinum neurotoxin for treating limb spasticity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20241217 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20241217 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241217 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241220 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241220 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241220 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20250117 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250117 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250306 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250307 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250307 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20250307 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250414 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250414 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250414 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250707 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250707 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250715 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251211 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251211 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260309 |